The Quantellect read.As of Nov 19, 2026, 7 active firms cover Monte Rosa Therapeutics Inc: 7 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $19.00 to $37.00, a moderate spread. The average target of $27.14 sits 199% above the current $9.07. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.46 next quarter toward $-1.78 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy7100%
Neutral00%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$27.14
+199.1% upside
Average target across 7 active firms as of Nov 19, 2026 vs $9.08 current
Highest Target$37.00
Average Target$27.14
Lowest Target$19.00
Detailed analyst forecasts for GLUE
Showing 1–7 of 7 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 7 of 7 active firms rate GLUE a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
GLUE EPS & revenue forecast
EPS · NEXT QUARTER
$-0.46
Range $-0.73 – $0.06 · 5 analysts · +3% YoY
Next period, 5 analysts expect Monte Rosa Therapeutics Inc to earn $-0.46 a share (range $-0.73 – $0.06), versus $-0.45 a year earlier. Full-year consensus is $-1.02, growing to $-1.78 the year after.
REVENUE · NEXT QUARTER
$3.9M
Range $0 – $10.0M · 5 analysts · -7% YoY
Revenue is expected to reach $3.9M (range $0 – $10.0M), -7.0% year-over-year. Full-year consensus is $102.3M, rising to $62.2M next year.
Top analysts covering Monte Rosa Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GLUE.
#1
Michael Schmidt
Guggenheim · Rank #4
Buy
$28.00+208.5% to target
Overall win rate
53%
+ Follow
#2
Brian Cheng
JP Morgan · Rank #87
Buy
$27.00+197.5% to target
Overall win rate
51%
+ Follow
#3
Mitchell Kapoor
HC Wainwright & Co. · Rank #305
Buy
$25.00+175.5% to target
Overall win rate
33%
+ Follow
#4
Edward Tenthoff
Piper Sandler · Rank #460
Buy
$37.00+307.7% to target
Overall win rate
29%
+ Follow
#5
Derek Archila
Wells Fargo · Rank #481
Buy
$27.00+197.5% to target
Overall win rate
36%
+ Follow
GLUE stock forecast FAQ
What is GLUE's average 12-month price target?+
The 7 active firms with a live target average $27.14 for Monte Rosa Therapeutics Inc over the next 12 months, ranging from a $37.00 high to a $19.00 low, as of Nov 19, 2026.
Is GLUE stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for GLUE?+
The Street-high target is $37.00 (Piper Sandler), and the Street-low is $19.00 (UBS). The average of all 7 active-firm targets is $27.14.
How many active Wall Street firms cover GLUE?+
7 active firms have a recognized rating on Monte Rosa Therapeutics Inc as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering GLUE?+
Among analysts who currently cover GLUE, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #4). Their current call is Buy with a $28.00 target.
What is Monte Rosa Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.46 per share (range $-0.73 – $0.06) across 5 analysts. Full-year EPS is projected at $-1.02, rising to $-1.78 the following year.
How much revenue is Monte Rosa Therapeutics Inc expected to report next quarter?+
Consensus revenue is $3.9M (range $0 – $10.0M). Full-year revenue is projected at $102.3M, growing to $62.2M next year.
Have analysts been upgrading or downgrading GLUE lately?+
As of Nov 19, 2026, 7 of 7 active firms rate GLUE a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GLUE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.